You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameHydralazine
Accession NumberDB01275
TypeSmall Molecule
GroupsApproved
DescriptionA direct-acting vasodilator that is used as an antihypertensive agent. [PubChem]
Structure
Thumb
Synonyms
(1Z)-1(2H)-Phthalazinone hydrazone
(2H)-Phthalazinone hydrazone
1-Hydrazinophthalazine
1-Phthalazinylhydrazine
6-Hydralazine
Hidralazina
Hydralazin
Hydralazinum
Hydrallazine
Hydrazinophthalazine
Hydrazone 1(2H)-phthalazinone
Hypophthalin
Idralazina
Phthalazin-1-ylhydrazine
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ApresolineSolution20 mgIntravenousSterimax Inc1992-12-31Not applicableCanada
Apresoline Tablets, 10mgTablet10 mgOralSterimax Inc1952-12-312005-07-22Canada
Apresoline Tablets, 25mgTablet25 mgOralSterimax Inc1952-12-312005-07-19Canada
Apresoline Tablets, 50mgTablet50 mgOralSterimax Inc1952-12-312005-07-19Canada
HydralazineTablet10 mgOralAa Pharma Inc1990-12-31Not applicableCanada
HydralazineTablet25 mgOralAa Pharma Inc1991-12-31Not applicableCanada
HydralazineTablet50 mgOralAa Pharma Inc1991-12-31Not applicableCanada
Hydralazine Hydrochloride InjectionSolution20 mgIntravenousFresenius Kabi Canada LtdNot applicableNot applicableCanada
Hydralazine-10 Tab 10mgTablet10 mgOralPro Doc Limitee1991-12-312010-07-13Canada
Hydralazine-25 TabTablet25 mgOralPro Doc Limitee1994-12-312010-07-13Canada
Hydralazine-50 TabTablet50 mgOralPro Doc Limitee1994-12-312010-07-13Canada
Jamp-hydralazineTablet50 mgOralJamp Pharma CorporationNot applicableNot applicableCanada
Jamp-hydralazineTablet10 mgOralJamp Pharma CorporationNot applicableNot applicableCanada
Jamp-hydralazineTablet25 mgOralJamp Pharma CorporationNot applicableNot applicableCanada
Novo-hylazin Tab 10mg USPTablet10 mgOralNovopharm Limited1992-12-312012-05-08Canada
Novo-hylazin Tab 25mgTablet25 mgOralNovopharm Limited1987-12-312012-05-09Canada
Novo-hylazin Tab 50mgTablet50 mgOralNovopharm Limited1987-12-312012-05-09Canada
Nu-hydral Tab 10mgTablet10 mgOralNu Pharm Inc1992-12-312012-09-04Canada
Nu-hydral Tab 25mgTablet25 mgOralNu Pharm Inc1992-12-312012-09-04Canada
Nu-hydral Tab 50 mgTablet50 mgOralNu Pharm Inc1992-12-312012-09-04Canada
PMS-hydralazineTablet10 mgOralPharmascience IncNot applicableNot applicableCanada
PMS-hydralazineTablet25 mgOralPharmascience IncNot applicableNot applicableCanada
PMS-hydralazineTablet50 mgOralPharmascience IncNot applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
HydralazineTablet25 mg/1OralCardinal Health2009-09-14Not applicableUs
HydralazineTablet50 mg/1OralCardinal Health2009-09-14Not applicableUs
Hydralazine HydrochlorideTablet100 mg/1OralCamber Pharmaceuticals2010-01-01Not applicableUs
Hydralazine HydrochlorideTablet10 mg/1OralPar Pharmaceutical, Inc.1982-10-05Not applicableUs
Hydralazine HydrochlorideTablet25 mg/1OralREMEDYREPACK INC.2013-05-13Not applicableUs
Hydralazine HydrochlorideInjection, solution20 mg/mLIntramuscular; IntravenousPhysicians Total Care, Inc.2011-05-17Not applicableUs
Hydralazine HydrochlorideInjection20 mg/mLIntramuscular; IntravenousCardinal Health2011-01-31Not applicableUs
Hydralazine HydrochlorideInjection20 mg/mLIntramuscular; IntravenousFresenius Kabi USA, LLC2001-09-05Not applicableUs
Hydralazine HydrochlorideTablet50 mg/1OralGlenmark Pharmaceuticals Inc., Usa2009-06-01Not applicableUs
Hydralazine HydrochlorideTablet25 mg/1OralCardinal Health2008-03-18Not applicableUs
Hydralazine HydrochlorideTablet, film coated25 mg/1OralUnit Dose Services2007-04-06Not applicableUs
Hydralazine HydrochlorideTablet, film coated50 mg/1OralMajor Pharmaceuticals2015-05-14Not applicableUs
Hydralazine HydrochlorideTablet, film coated25 mg/1OralHeritage Pharmaceuticals Inc2007-04-06Not applicableUs
Hydralazine HydrochlorideTablet, film coated100 mg/1OralAphena Pharma Solutions Tennessee, Llc2007-04-06Not applicableUs
Hydralazine HydrochlorideTablet10 mg/1OralMylan Institutional Inc.2007-12-26Not applicableUs
Hydralazine HydrochlorideTablet50 mg/1OralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
Hydralazine HydrochlorideTablet50 mg/1OralCardinal Health2011-05-13Not applicableUs
Hydralazine HydrochlorideTablet, film coated10 mg/1OralSt Marys Medical Park Pharmacy2014-04-21Not applicableUs
Hydralazine HydrochlorideTablet50 mg/1OralAscend Laboratories, LLC2009-11-24Not applicableUs
Hydralazine HydrochlorideTablet50 mg/1OralREMEDYREPACK INC.2016-04-14Not applicableUs
Hydralazine HydrochlorideTablet, film coated10 mg/1OralREMEDYREPACK INC.2015-06-10Not applicableUs
Hydralazine HydrochlorideInjection, solution20 mg/mLIntramuscular; IntravenousAmerican Regent, Inc.1997-06-30Not applicableUs
Hydralazine HydrochlorideTablet100 mg/1OralExelan Pharmaceuticals Inc.2016-05-20Not applicableUs
Hydralazine HydrochlorideTablet25 mg/1OralRebel Distributors Corp2008-09-12Not applicableUs
Hydralazine HydrochlorideInjection, solution20 mg/mLIntramuscular; IntravenousX Gen Pharmaceuticals, Inc.2015-06-29Not applicableUs
Hydralazine HydrochlorideTablet50 mg/1OralA S Medication Solutions Llc2010-01-01Not applicableUs
Hydralazine HydrochlorideInjection, solution20 mg/mLIntramuscular; IntravascularGeneral Injectables & Vaccines, Inc2011-10-19Not applicableUs
Hydralazine HydrochlorideTablet10 mg/1OralGolden State Medical Supply, Inc.2008-12-15Not applicableUs
Hydralazine HydrochlorideTablet25 mg/1OralCadila Pharmaceuticals Limited2014-09-24Not applicableUs
Hydralazine HydrochlorideTablet50 mg/1OralMc Kesson Contract Packaging2011-10-25Not applicableUs
Hydralazine HydrochlorideTablet25 mg/1OralClinical Solutions Wholesale2009-06-01Not applicableUs
Hydralazine HydrochlorideTablet50 mg/1OralTeva Pharmaceuticals Usa, Inc.1990-09-30Not applicableUs
Hydralazine HydrochlorideInjection, solution20 mg/mLIntramuscular; IntravenousMylan Institutional LLC2016-04-29Not applicableUs
Hydralazine HydrochlorideTablet100 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1983-09-27Not applicableUs
Hydralazine HydrochlorideTablet10 mg/1OralCamber Pharmaceuticals2010-01-01Not applicableUs
Hydralazine HydrochlorideTablet50 mg/1OralREMEDYREPACK INC.2011-12-09Not applicableUs
Hydralazine HydrochlorideTablet25 mg/1OralREMEDYREPACK INC.2013-06-03Not applicableUs
Hydralazine HydrochlorideTablet, film coated25 mg/1OralPhysicians Total Care, Inc.2007-09-17Not applicableUs
Hydralazine HydrochlorideTablet25 mg/1OralCardinal Health2009-12-07Not applicableUs
Hydralazine HydrochlorideTablet25 mg/1OralREMEDYREPACK INC.2014-10-24Not applicableUs
Hydralazine HydrochlorideTablet, film coated100 mg/1OralAmerican Health Packaging2011-09-19Not applicableUs
Hydralazine HydrochlorideTablet50 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-01-01Not applicableUs
Hydralazine HydrochlorideTablet100 mg/1OralPar Pharmaceutical, Inc.1983-09-27Not applicableUs
Hydralazine HydrochlorideTablet50 mg/1OralREMEDYREPACK INC.2014-06-11Not applicableUs
Hydralazine HydrochlorideInjection20 mg/mLIntramuscular; IntravenousCardinal Health2009-05-01Not applicableUs
Hydralazine HydrochlorideTablet25 mg/1OralStrides Pharma Inc2013-05-04Not applicableUs
Hydralazine HydrochlorideTablet100 mg/1Oralbryant ranch prepack2010-01-01Not applicableUs
Hydralazine HydrochlorideTablet100 mg/1OralGlenmark Pharmaceuticals Inc., Usa2009-06-01Not applicableUs
Hydralazine HydrochlorideTablet50 mg/1OralCardinal Health2008-03-18Not applicableUs
Hydralazine HydrochlorideTablet10 mg/1OralExelan Pharmaceuticals Inc.2016-05-20Not applicableUs
Hydralazine HydrochlorideTablet, film coated100 mg/1OralMajor Pharmaceuticals2015-05-14Not applicableUs
Hydralazine HydrochlorideTablet, film coated50 mg/1OralHeritage Pharmaceuticals Inc2007-04-06Not applicableUs
Hydralazine HydrochlorideTablet, film coated25 mg/1OralSafecor Health, LLC2014-09-30Not applicableUs
Hydralazine HydrochlorideTablet25 mg/1OralMylan Institutional Inc.2007-12-26Not applicableUs
Hydralazine HydrochlorideTablet25 mg/1OralA S Medication Solutions Llc2010-01-01Not applicableUs
Hydralazine HydrochlorideTablet10 mg/1OralCardinal Health2011-05-13Not applicableUs
Hydralazine HydrochlorideTablet, film coated50 mg/1OralSt Marys Medical Park Pharmacy2014-04-21Not applicableUs
Hydralazine HydrochlorideTablet25 mg/1OralAscend Laboratories, LLC2010-05-24Not applicableUs
Hydralazine HydrochlorideTablet25 mg/1OralREMEDYREPACK INC.2016-04-13Not applicableUs
Hydralazine HydrochlorideTablet50 mg/1Oralbryant ranch prepack2010-01-01Not applicableUs
Hydralazine HydrochlorideTablet10 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1982-10-05Not applicableUs
Hydralazine HydrochlorideTablet25 mg/1OralStrides Shasun Limited2013-06-30Not applicableUs
Hydralazine HydrochlorideTablet50 mg/1OralClinical Solutions Wholesale2009-06-01Not applicableUs
Hydralazine HydrochlorideTablet, film coated25 mg/1OralREMEDYREPACK INC.2009-11-03Not applicableUs
Hydralazine HydrochlorideTablet50 mg/1OralRebel Distributors Corp2008-09-12Not applicableUs
Hydralazine HydrochlorideTablet, film coated50 mg/1OralPd Rx Pharmaceuticals, Inc.2007-04-06Not applicableUs
Hydralazine HydrochlorideTablet, film coated10 mg/1OralUnit Dose Services2007-04-06Not applicableUs
Hydralazine HydrochlorideInjection, solution20 mg/mLIntramuscular; IntravenousGeneral Injectables & Vaccines, Inc2010-08-01Not applicableUs
Hydralazine HydrochlorideTablet, film coated10 mg/1OralCardinal Health2007-04-06Not applicableUs
Hydralazine HydrochlorideTablet25 mg/1OralGolden State Medical Supply, Inc.2008-12-15Not applicableUs
Hydralazine HydrochlorideTablet50 mg/1OralCadila Pharmaceuticals Limited2014-09-24Not applicableUs
Hydralazine HydrochlorideTablet, film coated25 mg/1OralAmerican Health Packaging2008-03-18Not applicableUs
Hydralazine HydrochlorideTablet10 mg/1OralGlenmark Pharmaceuticals Inc., Usa2009-06-01Not applicableUs
Hydralazine HydrochlorideTablet100 mg/1OralTeva Pharmaceuticals Usa, Inc.1990-09-30Not applicableUs
Hydralazine HydrochlorideTablet25 mg/1OralNu Care Pharmaceuticals, Inc.2010-01-01Not applicableUs
Hydralazine HydrochlorideTablet, film coated10 mg/1OralMajor Pharmaceuticals2015-05-14Not applicableUs
Hydralazine HydrochlorideTablet25 mg/1OralCamber Pharmaceuticals2010-01-01Not applicableUs
Hydralazine HydrochlorideTablet25 mg/1OralPar Pharmaceutical, Inc.1980-02-27Not applicableUs
Hydralazine HydrochlorideTablet50 mg/1OralREMEDYREPACK INC.2013-05-28Not applicableUs
Hydralazine HydrochlorideTablet, film coated50 mg/1OralPhysicians Total Care, Inc.2007-09-17Not applicableUs
Hydralazine HydrochlorideTablet10 mg/1OralCardinal Health2009-12-07Not applicableUs
Hydralazine HydrochlorideInjection20 mg/mLIntramuscular; IntravenousAkorn, Inc.2013-02-21Not applicableUs
Hydralazine HydrochlorideTablet25 mg/1OralLake Erie Medical DBA Quality Care Products LLC2009-06-01Not applicableUs
Hydralazine HydrochlorideTablet25 mg/1OralA S Medication Solutions Llc2010-01-01Not applicableUs
Hydralazine HydrochlorideTablet100 mg/1OralREMEDYREPACK INC.2014-06-11Not applicableUs
Hydralazine HydrochlorideInjection20 mg/mLIntramuscular; IntravenousCardinal Health2009-05-01Not applicableUs
Hydralazine HydrochlorideTablet50 mg/1OralStrides Pharma Inc2013-05-04Not applicableUs
Hydralazine HydrochlorideTablet25 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation1990-09-30Not applicableUs
Hydralazine HydrochlorideTablet10 mg/1OralMc Kesson Contract Packaging2011-12-02Not applicableUs
Hydralazine HydrochlorideTablet10 mg/1OralCardinal Health2010-09-10Not applicableUs
Hydralazine HydrochlorideTablet25 mg/1OralExelan Pharmaceuticals Inc.2016-05-20Not applicableUs
Hydralazine HydrochlorideTablet25 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1980-02-27Not applicableUs
Hydralazine HydrochlorideTablet, film coated100 mg/1OralHeritage Pharmaceuticals Inc2007-04-06Not applicableUs
Hydralazine HydrochlorideTablet25 mg/1OralREMEDYREPACK INC.2010-11-182016-10-13Us
Hydralazine HydrochlorideTablet50 mg/1OralMylan Institutional Inc.2007-12-26Not applicableUs
Hydralazine HydrochlorideTablet50 mg/1OralA S Medication Solutions Llc2010-01-01Not applicableUs
Hydralazine HydrochlorideTablet25 mg/1OralCardinal Health2011-05-13Not applicableUs
Hydralazine HydrochlorideTablet, film coated25 mg/1OralSt Marys Medical Park Pharmacy2014-04-21Not applicableUs
Hydralazine HydrochlorideTablet10 mg/1OralAscend Laboratories, LLC2010-05-24Not applicableUs
Hydralazine HydrochlorideInjection20 mg/mLIntramuscular; IntravenousAkorn, Inc.2009-05-01Not applicableUs
Hydralazine HydrochlorideTablet100 mg/1OralAphena Pharma Solutions Tennessee, Llc1990-09-30Not applicableUs
Hydralazine HydrochlorideTablet50 mg/1OralGolden State Medical Supply, Inc.2008-12-15Not applicableUs
Hydralazine HydrochlorideTablet100 mg/1OralCadila Pharmaceuticals Limited2014-09-24Not applicableUs
Hydralazine HydrochlorideTablet50 mg/1OralStrides Shasun Limited2013-06-30Not applicableUs
Hydralazine HydrochlorideTablet100 mg/1OralClinical Solutions Wholesale2009-06-01Not applicableUs
Hydralazine HydrochlorideTablet50 mg/1OralA S Medication Solutions2009-06-01Not applicableUs
Hydralazine HydrochlorideTablet100 mg/1OralRebel Distributors Corp2008-09-12Not applicableUs
Hydralazine HydrochlorideTablet, film coated50 mg/1OralAphena Pharma Solutions Tennessee, Llc2007-04-06Not applicableUs
Hydralazine HydrochlorideTablet, film coated25 mg/1OralUnit Dose Services2007-04-06Not applicableUs
Hydralazine HydrochlorideTablet, film coated50 mg/1OralAidarex Pharmaceuticals LLC2007-04-06Not applicableUs
Hydralazine HydrochlorideTablet, film coated100 mg/1OralCardinal Health2007-04-06Not applicableUs
Hydralazine HydrochlorideTablet, film coated10 mg/1OralPhysicians Total Care, Inc.2007-07-13Not applicableUs
Hydralazine HydrochlorideInjection20 mg/mLIntramuscular; IntravenousCardinal Health2011-01-31Not applicableUs
Hydralazine HydrochlorideTablet, film coated50 mg/1OralAmerican Health Packaging2008-03-18Not applicableUs
Hydralazine HydrochlorideTablet25 mg/1OralGlenmark Pharmaceuticals Inc., Usa2009-06-01Not applicableUs
Hydralazine HydrochlorideTablet10 mg/1OralTeva Pharmaceuticals Usa, Inc.1990-09-30Not applicableUs
Hydralazine HydrochlorideTablet10 mg/1OralNu Care Pharmaceuticals, Inc.2010-01-01Not applicableUs
Hydralazine HydrochlorideTablet, film coated25 mg/1OralMajor Pharmaceuticals2015-05-14Not applicableUs
Hydralazine HydrochlorideTablet50 mg/1OralCamber Pharmaceuticals2010-01-01Not applicableUs
Hydralazine HydrochlorideTablet50 mg/1OralPar Pharmaceutical, Inc.1980-02-27Not applicableUs
Hydralazine HydrochlorideTablet50 mg/1OralREMEDYREPACK INC.2013-07-01Not applicableUs
Hydralazine HydrochlorideTablet10 mg/1OralRebel Distributors Corp2008-09-12Not applicableUs
Hydralazine HydrochlorideTablet10 mg/1OralLake Erie Medical DBA Quality Care Products LLC2009-06-01Not applicableUs
Hydralazine HydrochlorideTablet25 mg/1OralA S Medication Solutions Llc2009-06-01Not applicableUs
Hydralazine HydrochlorideTablet10 mg/1OralREMEDYREPACK INC.2014-07-09Not applicableUs
Hydralazine HydrochlorideTablet100 mg/1OralStrides Pharma Inc2013-05-04Not applicableUs
Hydralazine HydrochlorideTablet50 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation1990-09-30Not applicableUs
Hydralazine HydrochlorideTablet25 mg/1OralMc Kesson Contract Packaging2011-10-25Not applicableUs
Hydralazine HydrochlorideTablet10 mg/1OralClinical Solutions Wholesale2009-06-01Not applicableUs
Hydralazine HydrochlorideTablet50 mg/1OralExelan Pharmaceuticals Inc.2016-05-20Not applicableUs
Hydralazine HydrochlorideTablet50 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1980-02-27Not applicableUs
Hydralazine HydrochlorideTablet10 mg/1OralREMEDYREPACK INC.2013-03-182016-10-26Us
Hydralazine HydrochlorideTablet, film coated25 mg/1OralREMEDYREPACK INC.2011-04-192016-10-13Us
Hydralazine HydrochlorideTablet10 mg/1OralREMEDYREPACK INC.2013-05-02Not applicableUs
Hydralazine HydrochlorideTablet, film coated100 mg/1OralPhysicians Total Care, Inc.2007-04-10Not applicableUs
Hydralazine HydrochlorideInjection, solution20 mg/mLIntramuscular; IntravenousCardinal Health1997-06-30Not applicableUs
Hydralazine HydrochlorideTablet50 mg/1OralREMEDYREPACK INC.2014-09-12Not applicableUs
Hydralazine HydrochlorideTablet, film coated10 mg/1OralAmerican Health Packaging2010-09-10Not applicableUs
Hydralazine HydrochlorideTablet25 mg/1OralTeva Pharmaceuticals Usa, Inc.1990-09-30Not applicableUs
Hydralazine HydrochlorideTablet100 mg/1OralAphena Pharma Solutions Tennessee, Llc2016-05-20Not applicableUs
Hydralazine HydrochlorideTablet50 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Hydralazine HydrochlorideTablet, film coated10 mg/1OralCardinal Health2007-04-06Not applicableUs
Hydralazine HydrochlorideTablet100 mg/1OralGolden State Medical Supply, Inc.2008-12-15Not applicableUs
Hydralazine HydrochlorideTablet100 mg/1OralAscend Laboratories, LLC2010-05-24Not applicableUs
Hydralazine HydrochlorideTablet100 mg/1OralStrides Shasun Limited2013-06-30Not applicableUs
Hydralazine HydrochlorideTablet25 mg/1OralREMEDYREPACK INC.2014-12-18Not applicableUs
Hydralazine HydrochlorideTablet10 mg/1OralREMEDYREPACK INC.2011-11-14Not applicableUs
Hydralazine HydrochlorideTablet, film coated10 mg/1OralHeritage Pharmaceuticals Inc2007-04-06Not applicableUs
Hydralazine HydrochlorideTablet, film coated25 mg/1OralAphena Pharma Solutions Tennessee, Llc2007-04-06Not applicableUs
Hydralazine HydrochlorideTablet, film coated50 mg/1OralUnit Dose Services2007-04-06Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AlphapressAlphapharm
AprezinJohnson
Cesoline WPharmasant
Cesoline YPharmasant
DiazideThe Central
HidralBiocontrol
PressfallNisshin Seiyaku
SerpathiazideWashington
Brand mixtures
NameLabellerIngredients
BidilArbor Pharmaceuticals
Ser-AP-ES TabNovartis Pharmaceuticals Canada Inc
Salts
Name/CASStructureProperties
Hydralazine hydrochloride
Thumb
  • InChI Key: ZUXNZUWOTSUBMN-UHFFFAOYSA-N
  • Monoisotopic Mass: 196.051574015
  • Average Mass: 196.637
DBSALT000792
Categories
UNII26NAK24LS8
CAS number86-54-4
WeightAverage: 160.1759
Monoisotopic: 160.074896276
Chemical FormulaC8H8N4
InChI KeyRPTUSVTUFVMDQK-UHFFFAOYSA-N
InChI
InChI=1S/C8H8N4/c9-11-8-7-4-2-1-3-6(7)5-10-12-8/h1-5H,9H2,(H,11,12)
IUPAC Name
1-hydrazinylphthalazine
SMILES
NNC1=NN=CC2=CC=CC=C12
Pharmacology
IndicationFor the treatment of essential hypertension, alone or as an adjunct. Also for the management of severe hypertension when the drug cannot be given orally or when blood pressure must be lowered immediately, congestive heart failure (in combination with cardiac glycosides and diuretics and/or with isosorbide dinitrate), and hypertension secondary to pre-eclampsia/eclampsia.
Structured Indications
PharmacodynamicsA vasodilator, hydralazine works by relaxing blood vessels (arterioles more than venules) and increasing the supply of blood and oxygen to the heart while reducing its workload. It also functions as an antioxidant. It inhibits membrane-bound enzymes that form reactive oxygen species, such as superoxides. Excessive superoxide counteracts NO-induced vasodilation. It is commonly used in the condition of pregnancy called preeclampsia.
Mechanism of actionAlthough the precise mechanism of action of hydralazine is not fully understood, the major effects are on the cardiovascular system. Hydralazine apparently lowers blood pressure by exerting a peripheral vasodilating effect through a direct relaxation of vascular smooth muscle. It has also been suggested that cyclic 3',5'-adenosine monophosphate (cyclic AMP) mediates, at least partly, the relaxation of arterial smooth muscle by altering cellular calcium metabolism, which interferes with the calcium movements within the vascular smooth muscle that are responsible for initiating or maintaining the contractile state. In hypertensive patients, the hydralazine-induced decrease in blood pressure is accompanied by increased heart rate, cardiac output, and stroke volume, probably because of a reflex response to decreased peripheral resistance. The drug has no direct effect on the heart. Hydralazine may increase pulmonary arterial pressure, as well as coronary, splanchnic, cerebral, and renal blood flow. The preferential dilatation of arterioles, as compared to veins, minimizes postural hypotension and promotes the increase in cardiac output. Hydralazine usually increases renin activity in plasma, presumably as a result of increased secretion of renin by the renal juxtaglomerular cells in response to reflex sympathetic discharge. This increase in renin activity leads to the production of angiotensin II, which then causes stimulation of aldosterone and consequent sodium reabsorption. Tolerance to the antihypertensive effect of the drug develops during prolonged therapy, especially if a diuretic is not administered concurrently. In patients with CHF, hydralazine decreases systemic vascular resistance and increases cardiac output.
TargetKindPharmacological actionActionsOrganismUniProt ID
Membrane primary amine oxidaseProteinyes
inhibitor
HumanQ16853 details
Prolyl 4-hydroxylase subunit alpha-1Proteinunknown
inhibitor
HumanP13674 details
Related Articles
AbsorptionHydralazine is rapidly and extensively absorbed (up to 90%) from the gastrointestinal tract and undergoes extensive first-pass metabolism by genetic polymorphic acetylation. Oral bioavailability of hydralazine is dependent upon acetylator phenotype. Bioavailability is approximately 31% in slow acetylators and 10% in fast acetylators.
Volume of distributionNot Available
Protein binding87%
Metabolism

Hydralazine, when administered orally, undergoes extensive first-pass metabolism by genetic polymorphic acetylation, which is responsible for a threefold range of oral bioavailability. Intravenously administered hydralazine does not undergo first-pass metabolism and, therefore, is not affected by acetylator phenotype. After the drug reaches the systemic circulation, it is combined with endogenous aldehydes and ketones, including pyruvic acid, to form hydrazone metabolites. The active metabolites, hydralazine acetonide hydrazone and hydralazine pyruvate hydrazone, are equipotent with the parent, hydralazine.

SubstrateEnzymesProduct
Hydralazine
Not Available
Hydralazine acetone hydrazoneDetails
Hydralazine
Not Available
Hydralazine pyruvate hydrazoneDetails
Route of eliminationHydralazine undergoes extensive hepatic metabolism; it is excreted mainly in the form of metabolites in the urine.
Half life3 to 7 hours
ClearanceNot Available
ToxicityOral LD50 in rats: 173 and 187 mg/kg
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Hydralazine.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Hydralazine.Approved
AceclofenacAceclofenac may decrease the antihypertensive activities of Hydralazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Hydralazine is combined with Acetazolamide.Approved, Vet Approved
AcetovanilloneAcetovanillone may decrease the antihypertensive activities of Hydralazine.Investigational
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Hydralazine.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Hydralazine.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Hydralazine.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Hydralazine.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Hydralazine is combined with Aliskiren.Approved, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Hydralazine.Approved, Withdrawn
AmbrisentanHydralazine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineHydralazine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Hydralazine.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Hydralazine is combined with Amiodarone.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Hydralazine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Hydralazine.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Hydralazine is combined with Amphotericin B.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Hydralazine is combined with Amyl Nitrite.Approved
AnisodamineAnisodamine may decrease the antihypertensive activities of Hydralazine.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Hydralazine.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Hydralazine.Approved
ApremilastApremilast may decrease the antihypertensive activities of Hydralazine.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Hydralazine.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Hydralazine is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Hydralazine is combined with Arsenic trioxide.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Hydralazine.Approved
AzapropazoneAzapropazone may decrease the antihypertensive activities of Hydralazine.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Hydralazine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Hydralazine is combined with Azilsartan medoxomil.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Hydralazine.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Hydralazine.Experimental
BarbitalBarbital may increase the hypotensive activities of Hydralazine.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Barnidipine.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Hydralazine.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Hydralazine.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Hydralazine.Withdrawn
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Hydralazine.Withdrawn
BepridilBepridil may increase the hypotensive activities of Hydralazine.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Hydralazine.Approved
BethanidineBethanidine may increase the hypotensive activities of Hydralazine.Approved
Betulinic AcidBetulinic Acid may decrease the antihypertensive activities of Hydralazine.Investigational
BimatoprostBimatoprost may increase the hypotensive activities of Hydralazine.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Hydralazine.Approved
BortezomibThe risk or severity of adverse effects can be increased when Hydralazine is combined with Bortezomib.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Hydralazine.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Hydralazine.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Hydralazine.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Hydralazine.Approved
BromfenacBromfenac may decrease the antihypertensive activities of Hydralazine.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Bromocriptine.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Hydralazine.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Hydralazine.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Bupivacaine.Approved, Investigational
BupranololHydralazine may increase the hypotensive activities of Bupranolol.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Hydralazine is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Hydralazine.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Hydralazine.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Hydralazine.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Hydralazine is combined with Carbetocin.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Hydralazine.Withdrawn
CarprofenCarprofen may decrease the antihypertensive activities of Hydralazine.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Hydralazine.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Carvedilol is combined with Hydralazine.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Hydralazine.Experimental
CelecoxibCelecoxib may decrease the antihypertensive activities of Hydralazine.Approved, Investigational
CeliprololHydralazine may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChloroquineChloroquine may decrease the antihypertensive activities of Hydralazine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Hydralazine.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Chlorpromazine.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Hydralazine.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Hydralazine is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Cilnidipine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Clofarabine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Hydralazine.Approved
ClonixinClonixin may decrease the antihypertensive activities of Hydralazine.Approved
ClozapineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Clozapine.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Hydralazine is combined with Conivaptan.Approved, Investigational
CryptenamineCryptenamine may increase the hypotensive activities of Hydralazine.Approved
CurcuminCurcumin may decrease the antihypertensive activities of Hydralazine.Investigational
CyclothiazideCyclothiazide may increase the hypotensive activities of Hydralazine.Approved
D-LimoneneD-Limonene may decrease the antihypertensive activities of Hydralazine.Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Hydralazine is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Hydralazine.Investigational
DebrisoquinHydralazine may increase the hypotensive activities of Debrisoquin.Approved
DeserpidineHydralazine may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Hydralazine is combined with Desflurane.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Hydralazine.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Hydralazine.Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Hydralazine.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Hydralazine.Approved
DiflunisalDiflunisal may decrease the antihypertensive activities of Hydralazine.Approved
DihydralazineHydralazine may increase the hypotensive activities of Dihydralazine.Investigational
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Hydralazine.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Hydralazine is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Hydralazine.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Hydralazine.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Hydralazine.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Hydralazine.Approved
DuloxetineHydralazine may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Hydralazine.Investigational
E6201E6201 may decrease the antihypertensive activities of Hydralazine.Investigational
EbselenEbselen may decrease the antihypertensive activities of Hydralazine.Investigational
EfonidipineHydralazine may increase the hypotensive activities of Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Hydralazine is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Hydralazine.Approved, Vet Approved
EnalaprilatHydralazine may increase the hypotensive activities of Enalaprilat.Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Hydralazine.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Hydralazine.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Hydralazine.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Hydralazine.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Hydralazine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Hydralazine.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Hydralazine.Approved, Investigational
EtodolacEtodolac may decrease the antihypertensive activities of Hydralazine.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Hydralazine.Approved
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Hydralazine.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Hydralazine.Approved
exisulindexisulind may decrease the antihypertensive activities of Hydralazine.Investigational
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Hydralazine.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Hydralazine.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Hydralazine.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Hydralazine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Hydralazine is combined with Fimasartan.Approved
FloctafenineFloctafenine may decrease the antihypertensive activities of Hydralazine.Approved, Withdrawn
FlunixinFlunixin may decrease the antihypertensive activities of Hydralazine.Vet Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Hydralazine.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Hydralazine.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Hydralazine.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Hydralazine.Approved, Vet Approved
GuanabenzGuanabenz may increase the hypotensive activities of Hydralazine.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Hydralazine.Approved
GuanethidineGuanethidine may increase the hypotensive activities of Hydralazine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Hydralazine.Approved, Investigational
HalothaneThe risk or severity of adverse effects can be increased when Hydralazine is combined with Halothane.Approved, Vet Approved
HexamethoniumHydralazine may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Hydralazine.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Hydralazine.Investigational
HMPL-004HMPL-004 may decrease the antihypertensive activities of Hydralazine.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Hydralazine.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Hydralazine.Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Hydralazine.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Hydralazine.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Hydralazine.Approved
IloprostIloprost may increase the hypotensive activities of Hydralazine.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Hydralazine is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Imipramine.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Hydralazine.Approved
IndenololHydralazine may increase the hypotensive activities of Indenolol.Withdrawn
IndomethacinIndomethacin may decrease the antihypertensive activities of Hydralazine.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Hydralazine.Withdrawn
IndoraminHydralazine may increase the hypotensive activities of Indoramin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Hydralazine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Hydralazine.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Hydralazine.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Hydralazine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Hydralazine is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Hydralazine.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Hydralazine.Approved
IsoxicamIsoxicam may decrease the antihypertensive activities of Hydralazine.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Hydralazine.Approved
KebuzoneKebuzone may decrease the antihypertensive activities of Hydralazine.Experimental
KetanserinHydralazine may increase the hypotensive activities of Ketanserin.Investigational
KetoprofenKetoprofen may decrease the antihypertensive activities of Hydralazine.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Hydralazine.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Hydralazine.Approved
LacidipineHydralazine may increase the hypotensive activities of Lacidipine.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Hydralazine.Approved, Investigational
LeflunomideLeflunomide may decrease the antihypertensive activities of Hydralazine.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Hydralazine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Hydralazine.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Levobupivacaine.Approved
LevodopaHydralazine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Hydralazine is combined with Levosimendan.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Hydralazine.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Hydralazine.Investigational
LofexidineHydralazine may increase the hypotensive activities of Lofexidine.Approved, Investigational
LornoxicamLornoxicam may decrease the antihypertensive activities of Hydralazine.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Hydralazine.Approved
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Hydralazine.Approved
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Hydralazine.Approved, Investigational
MacitentanHydralazine may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Hydralazine.Approved
ManidipineHydralazine may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Hydralazine.Approved, Investigational
MasoprocolMasoprocol may decrease the antihypertensive activities of Hydralazine.Approved
MebanazineMebanazine may increase the hypotensive activities of Hydralazine.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Hydralazine.Approved
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Hydralazine.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Hydralazine.Approved
MeloxicamMeloxicam may decrease the antihypertensive activities of Hydralazine.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Hydralazine.Approved
MetamizoleMetamizole may decrease the antihypertensive activities of Hydralazine.Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Hydralazine.Approved
MethohexitalMethohexital may increase the hypotensive activities of Hydralazine.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Hydralazine.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Hydralazine.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Hydralazine.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Hydralazine.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Hydralazine.Approved
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Hydralazine.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Hydralazine.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Hydralazine.Approved, Investigational
MetyrosineHydralazine may increase the hypotensive activities of Metyrosine.Approved
MibefradilHydralazine may increase the hypotensive activities of Mibefradil.Withdrawn
MinaprineMinaprine may increase the hypotensive activities of Hydralazine.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Hydralazine.Approved
MizoribineMizoribine may decrease the antihypertensive activities of Hydralazine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Hydralazine.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Hydralazine.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Hydralazine.Approved
MorphineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Morphine.Approved, Investigational
MoxonidineHydralazine may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Hydralazine.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Hydralazine.Approved
NabiloneThe risk or severity of adverse effects can be increased when Hydralazine is combined with Nabilone.Approved, Investigational
NabumetoneNabumetone may decrease the antihypertensive activities of Hydralazine.Approved
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Hydralazine.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Hydralazine.Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Hydralazine.Approved
NaftopidilHydralazine may increase the hypotensive activities of Naftopidil.Investigational
NaproxenNaproxen may decrease the antihypertensive activities of Hydralazine.Approved, Vet Approved
NCX 4016NCX 4016 may decrease the antihypertensive activities of Hydralazine.Investigational
NebivololThe risk or severity of adverse effects can be increased when Hydralazine is combined with Nebivolol.Approved, Investigational
NepafenacNepafenac may decrease the antihypertensive activities of Hydralazine.Approved
NesiritideThe risk or severity of adverse effects can be increased when Hydralazine is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Hydralazine.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Hydralazine.Approved
NicorandilNicorandil may increase the hypotensive activities of Hydralazine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Hydralazine.Approved
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Hydralazine.Approved
NiguldipineHydralazine may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineHydralazine may increase the hypotensive activities of Nilvadipine.Approved
NimesulideNimesulide may decrease the antihypertensive activities of Hydralazine.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Hydralazine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Hydralazine.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Hydralazine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Hydralazine is combined with Nitric Oxide.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Hydralazine.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Hydralazine.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Hydralazine.Approved
ObinutuzumabHydralazine may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Hydralazine.Withdrawn
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Hydralazine.Approved, Investigational
OlopatadineOlopatadine may decrease the antihypertensive activities of Hydralazine.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Hydralazine.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Hydralazine.Investigational
OrgoteinOrgotein may decrease the antihypertensive activities of Hydralazine.Vet Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Hydralazine.Approved
OxprenololHydralazine may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Hydralazine.Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Hydralazine is combined with Paclitaxel.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Hydralazine.Approved
ParecoxibParecoxib may decrease the antihypertensive activities of Hydralazine.Approved
PargylinePargyline may increase the hypotensive activities of Hydralazine.Approved
PenbutololThe risk or severity of adverse effects can be increased when Hydralazine is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Hydralazine.Approved, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Hydralazine.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Hydralazine.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Hydralazine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Hydralazine.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Hydralazine.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Hydralazine.Approved
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Hydralazine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Hydralazine.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Hydralazine.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Hydralazine.Approved, Vet Approved
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Hydralazine.Approved, Investigational
PinacidilHydralazine may increase the hypotensive activities of Pinacidil.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Hydralazine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Hydralazine is combined with Pipamperone.Approved
PirfenidonePirfenidone may decrease the antihypertensive activities of Hydralazine.Investigational
PirlindolePirlindole may increase the hypotensive activities of Hydralazine.Approved
PiroxicamPiroxicam may decrease the antihypertensive activities of Hydralazine.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Hydralazine.Withdrawn
PolythiazideHydralazine may increase the hypotensive activities of Polythiazide.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Hydralazine is combined with Pramipexole.Approved, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Hydralazine.Approved
PrimidonePrimidone may increase the hypotensive activities of Hydralazine.Approved, Vet Approved
PropacetamolPropacetamol may decrease the antihypertensive activities of Hydralazine.Approved
PropofolThe risk or severity of adverse effects can be increased when Hydralazine is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Hydralazine.Approved, Investigational
PTC299PTC299 may decrease the antihypertensive activities of Hydralazine.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Hydralazine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Hydralazine.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Hydralazine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Hydralazine.Approved
RasagilineRasagiline may increase the hypotensive activities of Hydralazine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Hydralazine is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Hydralazine.Approved
RescinnamineHydralazine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Hydralazine.Approved
ResveratrolResveratrol may decrease the antihypertensive activities of Hydralazine.Experimental, Investigational
RilmenidineHydralazine may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Hydralazine is combined with Riociguat.Approved
RisperidoneHydralazine may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabHydralazine may increase the hypotensive activities of Rituximab.Approved
RofecoxibRofecoxib may decrease the antihypertensive activities of Hydralazine.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Hydralazine is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Hydralazine is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Hydralazine.Withdrawn
SalicylamideSalicylamide may decrease the antihypertensive activities of Hydralazine.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Hydralazine.Approved, Vet Approved
SalsalateSalsalate may decrease the antihypertensive activities of Hydralazine.Approved
SaprisartanHydralazine may increase the hypotensive activities of Saprisartan.Experimental
SecobarbitalSecobarbital may increase the hypotensive activities of Hydralazine.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Hydralazine.Approved, Investigational, Vet Approved
SelexipagHydralazine may increase the hypotensive activities of Selexipag.Approved
SeratrodastSeratrodast may decrease the antihypertensive activities of Hydralazine.Approved, Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Hydralazine is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Hydralazine.Approved, Investigational
SitaxentanHydralazine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Hydralazine is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Hydralazine.Approved
SpiraprilHydralazine may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Hydralazine.Approved
SRT501SRT501 may decrease the antihypertensive activities of Hydralazine.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Hydralazine is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Hydralazine is combined with Sufentanil.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Hydralazine.Approved
SulindacSulindac may decrease the antihypertensive activities of Hydralazine.Approved
SuprofenSuprofen may decrease the antihypertensive activities of Hydralazine.Approved, Withdrawn
TadalafilTadalafil may increase the antihypertensive activities of Hydralazine.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Hydralazine is combined with Tamsulosin.Approved, Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Hydralazine.Approved, Investigational
TemocaprilHydralazine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenoxicamTenoxicam may decrease the antihypertensive activities of Hydralazine.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Hydralazine.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Hydralazine.Approved
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Hydralazine.Approved
TerlipressinHydralazine may increase the hypotensive activities of Terlipressin.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Hydralazine is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Hydralazine.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Hydralazine.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Thioridazine.Approved
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Hydralazine.Approved
TiboloneHydralazine may increase the hypotensive activities of Tibolone.Approved
TicrynafenHydralazine may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Hydralazine.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Hydralazine.Investigational
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Hydralazine.Approved
TolazolineTolazoline may increase the hypotensive activities of Hydralazine.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Hydralazine is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Hydralazine.Approved
TolmetinTolmetin may decrease the antihypertensive activities of Hydralazine.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Hydralazine.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Hydralazine.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Hydralazine.Approved
TranilastTranilast may decrease the antihypertensive activities of Hydralazine.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Hydralazine.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Hydralazine.Approved
TravoprostTravoprost may increase the hypotensive activities of Hydralazine.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Hydralazine.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Hydralazine is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Hydralazine.Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Hydralazine.Approved, Vet Approved
TrimazosinHydralazine may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Hydralazine.Approved
Trisalicylate-cholineTrisalicylate-choline may decrease the antihypertensive activities of Hydralazine.Approved
UdenafilUdenafil may increase the antihypertensive activities of Hydralazine.Approved, Investigational
UnoprostoneHydralazine may increase the hypotensive activities of Unoprostone.Approved
ValdecoxibValdecoxib may decrease the antihypertensive activities of Hydralazine.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Hydralazine.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Hydralazine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Hydralazine.Approved
VinpocetineHydralazine may increase the hypotensive activities of Vinpocetine.Investigational
XylometazolineHydralazine may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Hydralazine.Approved, Vet Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Hydralazine.Approved
ZileutonZileuton may decrease the antihypertensive activities of Hydralazine.Approved, Investigational, Withdrawn
ZomepiracZomepirac may decrease the antihypertensive activities of Hydralazine.Withdrawn
Food InteractionsNot Available
References
Synthesis Reference

U.S. Patent 2,484,029.

General References
  1. Kandler MR, Mah GT, Tejani AM, Stabler SN: Hydralazine for essential hypertension. Cochrane Database Syst Rev. 2010 Aug 4;(8):CD004934. doi: 10.1002/14651858.CD004934.pub3. [PubMed:20687078 ]
External Links
ATC CodesC02DB02C02LG02
AHFS Codes
  • 24:08.20
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (73.7 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9854
Blood Brain Barrier+0.9487
Caco-2 permeable+0.8867
P-glycoprotein substrateNon-substrate0.686
P-glycoprotein inhibitor INon-inhibitor0.9478
P-glycoprotein inhibitor IINon-inhibitor0.9826
Renal organic cation transporterNon-inhibitor0.8279
CYP450 2C9 substrateNon-substrate0.8971
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.7467
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorInhibitor0.526
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5294
Ames testAMES toxic0.9107
CarcinogenicityNon-carcinogens0.7719
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.2187 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9253
hERG inhibition (predictor II)Non-inhibitor0.8589
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
SolutionIntravenous20 mg
Tablet, film coatedOral
TabletOral10 mg
TabletOral25 mg
TabletOral50 mg
InjectionIntramuscular; Intravenous20 mg/mL
Injection, solutionIntramuscular; Intravascular20 mg/mL
Injection, solutionIntramuscular; Intravenous20 mg/mL
TabletOral10 mg/1
TabletOral100 mg/1
TabletOral25 mg/1
TabletOral50 mg/1
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral25 mg/1
Tablet, film coatedOral50 mg/1
TabletOral
Prices
Unit descriptionCostUnit
Hydralazine 20 mg/ml vial18.0USD ml
Hydralazine 100 mg tablet1.65USD tablet
Hydralazine-HCTZ 50-50 mg capsule1.2USD capsule
HydrALAZINE HCl 100 mg tablet1.05USD tablet
Hydralazine-HCTZ 25-25 mg capsule0.81USD capsule
Hydralazine-HCTZ 100-50 mg capsule0.75USD capsule
HydrALAZINE HCl 50 mg tablet0.67USD tablet
Apresoline 50 mg tablet0.65USD tablet
HydrALAZINE HCl 25 mg tablet0.53USD tablet
HydrALAZINE HCl 10 mg tablet0.47USD tablet
Hydralazine 50 mg tablet0.44USD tablet
Hydralazine 25 mg tablet0.35USD tablet
Apo-Hydralazine 50 mg Tablet0.29USD tablet
Novo-Hylazin 50 mg Tablet0.29USD tablet
Apo-Hydralazine 25 mg Tablet0.24USD tablet
Hydralazine 10 mg tablet0.22USD tablet
Apo-Hydralazine 10 mg Tablet0.11USD tablet
Novo-Hylazin 10 mg Tablet0.11USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6465463 No2000-09-082020-09-08Us
US6784177 No2000-09-082020-09-08Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point172-173 °CU.S. Patent 2,484,029.
logP1.00SANGSTER (1993)
Predicted Properties
PropertyValueSource
Water Solubility2.61 mg/mLALOGPS
logP0.66ALOGPS
logP0.75ChemAxon
logS-1.8ALOGPS
pKa (Strongest Acidic)17.69ChemAxon
pKa (Strongest Basic)6.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area63.83 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity50.23 m3·mol-1ChemAxon
Polarizability16.06 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phthalazines. These are compounds containing a phthalazine moiety, which consists of a benzene ring fused to a pyridazine, forming a 2,3-benzodiazine skeleton.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassNaphthyridines
Sub ClassPhthalazines
Direct ParentPhthalazines
Alternative Parents
Substituents
  • Phthalazine
  • Aminopyridazine
  • Imidolactam
  • Benzenoid
  • Pyridazine
  • Heteroaromatic compound
  • Azacycle
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Hydrazine derivative
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Tryptamine:oxygen oxidoreductase (deaminating) activity
Specific Function:
Cell adhesion protein that participates in lymphocyte extravasation and recirculation by mediating the binding of lymphocytes to peripheral lymph node vascular endothelial cells in an L-selectin-independent fashion. Has semicarbazide-sensitive (SSAO) monoamine oxidase activity. May play a role in adipogenesis.
Gene Name:
AOC3
Uniprot ID:
Q16853
Molecular Weight:
84621.27 Da
References
  1. Claud P, Padovani P, Guichard JP, Artur Y, Laine R: Involvement of semicarbazide-sensitive amine oxidase in tresperimus metabolism in human and in rat. Drug Metab Dispos. 2001 May;29(5):735-41. [PubMed:11302941 ]
  2. Vidrio H, Medina M, Gonzalez-Romo P, Lorenzana-Jimenez M, Diaz-Arista P, Baeza A: Semicarbazide-sensitive amine oxidase substrates potentiate hydralazine hypotension: possible role of hydrogen peroxide. J Pharmacol Exp Ther. 2003 Nov;307(2):497-504. Epub 2003 Sep 11. [PubMed:12970383 ]
  3. Vidrio H: Semicarbazide-sensitive amine oxidase: role in the vasculature and vasodilation after in situ inhibition. Auton Autacoid Pharmacol. 2003 Oct-Dec;23(5-6):275-83. [PubMed:15255812 ]
  4. Vidrio H, Medina M: 2-bromoethylamine, a suicide inhibitor of semicarbazide-sensitive amine oxidase, increases hydralazine hypotension in rats. J Cardiovasc Pharmacol. 2005 Sep;46(3):316-24. [PubMed:16116337 ]
  5. Vidrio H, Medina M: Hypotensive effect of hydroxylamine, an endogenous nitric oxide donor and SSAO inhibitor. J Neural Transm (Vienna). 2007;114(6):863-5. Epub 2007 Mar 26. [PubMed:17385063 ]
  6. Gronvall JL, Garpenstrand H, Oreland L, Ekblom J: An autoradiographic method of visualising semicarbazide-sensitive amine oxidase activity in mouse tissue sections. Neurobiology (Bp). 2000;8(2):167-77. [PubMed:11061213 ]
  7. Gronvall JL, Garpenstrand H, Oreland L, Ekblom J: Autoradiographic imaging of formaldehyde adducts in mice: possible relevance for vascular damage in diabetes. Life Sci. 1998;63(9):759-68. [PubMed:9740313 ]
  8. Lizcano JM, Fernandez de Arriba A, Tipton KF, Unzeta M: Inhibition of bovine lung semicarbazide-sensitive amine oxidase (SSAO) by some hydrazine derivatives. Biochem Pharmacol. 1996 Jul 26;52(2):187-95. [PubMed:8694842 ]
  9. Lyles GA, McDougall SA: The enhanced daily excretion of urinary methylamine in rats treated with semicarbazide or hydralazine may be related to the inhibition of semicarbazide-sensitive amine oxidase activities. J Pharm Pharmacol. 1989 Feb;41(2):97-100. [PubMed:2568436 ]
  10. Barrand MA, Callingham BA: The interaction of hydralazine with a semicarbazide-sensitive amine oxidase in brown adipose tissue of the rat. Its use as a radioactive ligand for the enzyme. Biochem J. 1985 Dec 1;232(2):415-23. [PubMed:4091799 ]
  11. Barrand MA, Fox SA: Amine oxidase activities in brown adipose tissue of the rat: identification of semicarbazide-sensitive (clorgyline-resistant) activity at the fat cell membrane. J Pharm Pharmacol. 1984 Oct;36(10):652-8. [PubMed:6150080 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Procollagen-proline 4-dioxygenase activity
Specific Function:
Catalyzes the post-translational formation of 4-hydroxyproline in -Xaa-Pro-Gly- sequences in collagens and other proteins.
Gene Name:
P4HA1
Uniprot ID:
P13674
Molecular Weight:
61048.775 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Knowles HJ, Tian YM, Mole DR, Harris AL: Novel mechanism of action for hydralazine: induction of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by inhibition of prolyl hydroxylases. Circ Res. 2004 Jul 23;95(2):162-9. Epub 2004 Jun 10. [PubMed:15192023 ]
  3. Murad S, Tajima S, Pinnell SR: A paradoxical effect of hydralazine on prolyl and lysyl hydroxylase activities in cultured human skin fibroblasts. Arch Biochem Biophys. 1985 Sep;241(2):356-63. [PubMed:2994564 ]
  4. Chen KH, Paz MA, Gallop PM: Collagen prolyl hydroxylation in WI-38 fibroblast cultures: action of hydralazine. In Vitro. 1977 Jan;13(1):49-54. [PubMed:856725 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Zhao XJ, Ishizaki T: Metabolic interactions of selected antimalarial and non-antimalarial drugs with the major pathway (3-hydroxylation) of quinine in human liver microsomes. Br J Clin Pharmacol. 1997 Nov;44(5):505-11. [PubMed:9384469 ]
Comments
comments powered by Disqus
Drug created on May 16, 2007 14:38 / Updated on December 03, 2016 02:43